Valuation: Lundbeck

Market Cap 45.26B 6.78B 6.06B 5.65B 5.13B 9.66B 657B 9.75B 67.83B 26.53B 334B 25.46B 24.91B 1,073B P/E 2026 *
10.2x
P/E 2027 * 9.96x
Enterprise Value 49.27B 7.38B 6.59B 6.15B 5.59B 10.51B 715B 10.61B 73.83B 28.88B 363B 27.71B 27.11B 1,168B EV / Sales 2026 *
1.9x
EV / Sales 2027 * 1.73x
Free-Float
30.74%
Yield 2026 *
3.37%
Yield 2027 * 3.03%
1 day+0.57%
1 week+6.24%
Current month+3.75%
1 month+1.84%
3 months+22.04%
6 months+33.03%
Current year+22.38%
1 week 41.85
Extreme 41.85
44.4
1 month 38.75
Extreme 38.75
45
Current year 31.4
Extreme 31.4
45
1 year 31.4
Extreme 31.4
45
3 years 23.3
Extreme 23.3
45
5 years 21.94
Extreme 21.935
45
10 years 21.94
Extreme 21.935
45
Manager TitleAgeSince
Chief Executive Officer 59 30/09/2023
Director of Finance/CFO 49 31/08/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 24/03/2015
Director/Board Member 67 24/03/2015
Director/Board Member 60 19/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
-0.29%+6.24% - - 6.78B
-1.61%+1.72%+38.30%+106.93% 1,043B
-0.76%-0.84%+35.21%+62.70% 618B
+0.39%+4.81%+17.81%+83.77% 481B
-0.29%-0.99%+64.79%+37.06% 351B
+1.19%+3.36%+21.70%+42.44% 338B
+1.10%+2.49%+11.84%+35.30% 269B
+1.35%+1.47%-6.92%+10.94% 244B
-1.37%+0.04%+38.29%+52.33% 220B
+0.17%-0.27%+24.40%+96.82% 182B
Average +0.08%+0.28%+27.27%+58.70% 416.3B
Weighted average by Cap. -0.30%+0.60%+30.62%+69.20%

Financials

2026 *2027 *
Net sales 25.87B 3.88B 3.46B 3.23B 2.93B 5.52B 375B 5.57B 38.77B 15.16B 191B 14.55B 14.24B 613B 26.1B 3.91B 3.49B 3.26B 2.96B 5.57B 379B 5.62B 39.11B 15.3B 192B 14.68B 14.36B 619B
Net income 4.57B 684M 611M 570M 518M 974M 66.27B 984M 6.84B 2.68B 33.67B 2.57B 2.51B 108B 4.62B 692M 618M 577M 524M 986M 67.03B 995M 6.92B 2.71B 34.06B 2.6B 2.54B 110B
Net Debt 4B 600M 536M 500M 454M 854M 58.08B 862M 6B 2.35B 29.52B 2.25B 2.2B 94.92B -182M -27.24M -24.32M -22.69M -20.61M -38.79M -2.64B -39.16M -272M -107M -1.34B -102M -100M -4.31B
Projected Income Statement - Annual - Lundbeck
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
09/10/26 DKK 44.05 +0.46% 4,884
08/10/26 DKK 43.85 +0.92% 47,409
07/10/26 DKK 43.45 +0.58% 33,353
06/10/26 DKK 43.20 +1.41% 59,317
05/10/26 DKK 42.60 +2.16% 38,048
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Lundbeck
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
46.12DKK
Average target price
49.19DKK
Spread / Average Target
+6.66%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Lundbeck